Pluribus Labs’s Corteva CTVA Stock Holding History

Pluribus Labs’s Portfolio CTVA Stock Details CTVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-6,431	Closed	-$304K	–	99
2021 Q4	$304K	Buy	+6,431	New	+$293K	0.32%	132

Other funds holding CTVA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Aristotle Capital Management Los Angeles, California $47.8B AUM 13.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

IFP

Independent Franchise Partners London, United Kingdom $14.3B AUM 3.49% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Pluribus Labs's CTVA Position: Q1 2022 in Review

Pluribus Labs sold out of Corteva (CTVA) in Q1 2022, closing a stake of 6,431 shares — an estimated $304K sold.

Pluribus Labs first reported a position in CTVA in Q4 2021 and held it in 1 quarter. The position peaked at $304K in Q4 2021. 1,189 funds tracked by Wall St. Rank hold CTVA as of Q1 2022.

Pluribus Labs reported no remaining Corteva position as of Q1 2022 after selling out during the quarter.
Pluribus Labs sold 6,431 Corteva shares in Q1 2022, an estimated $304K.
Pluribus Labs first reported a position in Corteva in Q4 2021 and held it in 1 quarter.
Pluribus Labs's Corteva position peaked at $304K in Q4 2021.
1,189 funds tracked by Wall St. Rank held Corteva as of Q1 2022.

Based on Pluribus Labs's 13F filing for Q1 2022, filed 16 May 2022.